These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 27431778)

  • 1. New therapeutic strategies for malignant pleural mesothelioma.
    Bonelli MA; Fumarola C; La Monica S; Alfieri R
    Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a role for immunotherapy in malignant pleural mesothelioma?
    Tartarone A; Lerose R; Aieta M
    Med Oncol; 2018 May; 35(7):98. PubMed ID: 29845408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.
    Wong RM; Ianculescu I; Sharma S; Gage DL; Olevsky OM; Kotova S; Kostic MN; Grundfest WS; Hou D; Cameron RB
    Am J Respir Cell Mol Biol; 2014 May; 50(5):870-5. PubMed ID: 24450537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges.
    Ceresoli GL; Bonomi M; Sauta MG
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):673-5. PubMed ID: 27224058
    [No Abstract]   [Full Text] [Related]  

  • 5. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.
    Lee HS; Jang HJ; Choi JM; Zhang J; de Rosen VL; Wheeler TM; Lee JS; Tu T; Jindra PT; Kerman RH; Jung SY; Kheradmand F; Sugarbaker DJ; Burt BM
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant Pleural Mesothelioma: State of the art and advanced cell therapy.
    Facchetti G; Petrella F; Spaggiari L; Rimoldi I
    Eur J Med Chem; 2017 Dec; 142():266-270. PubMed ID: 28800871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updates in the diagnosis and treatment of malignant pleural mesothelioma.
    Katzman D; Sterman DH
    Curr Opin Pulm Med; 2018 Jul; 24(4):319-326. PubMed ID: 29553973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.
    Bononi A; Napolitano A; Pass HI; Yang H; Carbone M
    Expert Rev Respir Med; 2015 Oct; 9(5):633-54. PubMed ID: 26308799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
    Van den Bossche J; De Laere M; Deschepper K; Germonpré P; Valcke Y; Lamont J; Stein B; Van Camp K; Germonpré C; Nijs G; Roelant E; Anguille S; Lion E; Berneman Z
    PLoS One; 2024; 19(7):e0307204. PubMed ID: 39008481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular heterogeneity of malignant pleural mesotheliomas].
    Tranchant R; Montagne F; Jaurand MC; Jean D
    Bull Cancer; 2018 Jan; 105(1):35-45. PubMed ID: 29277245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in treatment of mesothelioma.
    Maggioni C; Barletta G; Rijavec E; Biello F; Gualco E; Grossi F
    Expert Opin Pharmacother; 2016 Jun; 17(9):1197-205. PubMed ID: 27055148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
    Schuberth PC; Hagedorn C; Jensen SM; Gulati P; van den Broek M; Mischo A; Soltermann A; Jüngel A; Marroquin Belaunzaran O; Stahel R; Renner C; Petrausch U
    J Transl Med; 2013 Aug; 11():187. PubMed ID: 23937772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma.
    Gray SG
    BMC Pulm Med; 2021 May; 21(1):148. PubMed ID: 33952230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
    J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of microRNAs in the diagnosis and treatment of malignant pleural mesothelioma--a short review.
    Sheff KW; Hoda MA; Dome B; Hegedus B; Klepetko W; Weiss GJ
    Microrna; 2012; 1(1):40-8. PubMed ID: 25048089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
    Bronte G; Incorvaia L; Rizzo S; Passiglia F; Galvano A; Rizzo F; Rolfo C; Fanale D; Listì A; Natoli C; Bazan V; Russo A
    Crit Rev Oncol Hematol; 2016 Nov; 107():20-32. PubMed ID: 27823648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Response of Live-Attenuated,
    Hassan R; Alley E; Kindler H; Antonia S; Jahan T; Honarmand S; Nair N; Whiting CC; Enstrom A; Lemmens E; Tsujikawa T; Kumar S; Choe G; Thomas A; McDougall K; Murphy AL; Jaffee E; Coussens LM; Brockstedt DG
    Clin Cancer Res; 2019 Oct; 25(19):5787-5798. PubMed ID: 31263030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic Approaches in Malignant Pleural Mesothelioma.
    Terenziani R; Zoppi S; Fumarola C; Alfieri R; Bonelli M
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunotherapy and malignant mesothelioma: clinical perspectives].
    Grégoire M; Ebstein F
    Bull Cancer; 2007 Jan; 94(1):23-31. PubMed ID: 17237002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Malignant pleural mesothelioma: 2013 state of the art].
    Campbell K; Brosseau S; Reviron-Rabec L; Bergot E; Lechapt E; Levallet G; Zalcman G
    Bull Cancer; 2013 Dec; 100(12):1283-93. PubMed ID: 24225007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.